Galmed Pharma, an Israeli biopharma, was approved to add a China arm to its global Phase III trial of Aramchol in patients with NASH and fibrosis. Aramchol is a novel fatty acid bile acid conjugate that targets SCD1 to modulate hepatic lipid metabolism. In animal models, it down regulated steatosis, inflammation and fibrosis, all NASH-associated pathologies. Galmed develops novel products to treat liver, metabolic and inflammatory diseases. More details.... Stock Symbol: (NSDQ: GLMD) Share this with colleagues: // //